-
Je něco špatně v tomto záznamu ?
Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality
K. Smetana, D. Rosel, J. Brábek,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2004 do Před 2 roky
PubMed Central
od 2017
Europe PubMed Central
od 2017
Open Access Digital Library
od 2004-01-01
PubMed
32871847
DOI
10.21873/invivo.12135
Knihovny.cz E-zdroje
- MeSH
- Betacoronavirus účinky léků patogenita MeSH
- cytokiny antagonisté a inhibitory genetika MeSH
- indoly farmakologie MeSH
- interleukin-6 antagonisté a inhibitory genetika MeSH
- koronavirové infekce farmakoterapie genetika mortalita virologie MeSH
- lidé MeSH
- pandemie MeSH
- raloxifen hydrochlorid farmakologie MeSH
- receptory pro estrogeny antagonisté a inhibitory MeSH
- selektivní modulátory estrogenních receptorů farmakologie MeSH
- signální transdukce účinky léků MeSH
- syndrom dechové tísně farmakoterapie prevence a kontrola virologie MeSH
- virová pneumonie farmakoterapie genetika mortalita virologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20024804
- 003
- CZ-PrNML
- 005
- 20220119145207.0
- 007
- ta
- 008
- 201125s2020 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/invivo.12135 $2 doi
- 035 __
- $a (PubMed)32871847
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Smetana, Karel $u Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic jan.brabek@natur.cuni.cz karel.smetana@lf1.cuni.cz. BIOCEV, Vestec, Czech Republic.
- 245 10
- $a Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality / $c K. Smetana, D. Rosel, J. Brábek,
- 520 9_
- $a The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.
- 650 _2
- $a Betacoronavirus $x účinky léků $x patogenita $7 D000073640
- 650 _2
- $a koronavirové infekce $x farmakoterapie $x genetika $x mortalita $x virologie $7 D018352
- 650 _2
- $a cytokiny $x antagonisté a inhibitory $x genetika $7 D016207
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a indoly $x farmakologie $7 D007211
- 650 _2
- $a interleukin-6 $x antagonisté a inhibitory $x genetika $7 D015850
- 650 _2
- $a pandemie $7 D058873
- 650 _2
- $a virová pneumonie $x farmakoterapie $x genetika $x mortalita $x virologie $7 D011024
- 650 _2
- $a raloxifen hydrochlorid $x farmakologie $7 D020849
- 650 _2
- $a receptory pro estrogeny $x antagonisté a inhibitory $7 D011960
- 650 _2
- $a syndrom dechové tísně $x farmakoterapie $x prevence a kontrola $x virologie $7 D012128
- 650 _2
- $a selektivní modulátory estrogenních receptorů $x farmakologie $7 D020845
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rosel, Daniel $u BIOCEV, Vestec, Czech Republic. Department of Cell Biology, Faculty of Sciences, Charles University, Prague, Czech Republic.
- 700 1_
- $a Brábek, Jan, $u BIOCEV, Vestec, Czech Republic jan.brabek@natur.cuni.cz karel.smetana@lf1.cuni.cz. Department of Cell Biology, Faculty of Sciences, Charles University, Prague, Czech Republic. $d 1973- $7 xx0268678
- 773 0_
- $w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 34, č. 5 (2020), s. 3027-3028
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32871847 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20220119145203 $b ABA008
- 999 __
- $a ok $b bmc $g 1598949 $s 1115490
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 34 $c 5 $d 3027-3028 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
- LZP __
- $a Pubmed-20201125